CONTENTS:
• Opioid addiction agonist therapy and the QT prolongation phenomenon: state of the science and evolving research questions [Editorial]. Wedam E.F., Haigney M.C., p. 1015-1017.
• Peak provoked craving: an alternative to smoking cue-reactivity [For debate]. Sayette M.A., Tiffany S.T., p. 1019-1025.
• Parsing peak provoked craving. Shiffman S., p. 1026-1027.
• Will peak provoked craving prove superior to cue-reactivity? Adams S., Munafò M.R., p. 1027-1028.
• Measuring craving for cigarettes: Should we measure more than just craving? McRobbie H., West O., p. 1028-1030.
• Peak-provoked craving deserves a seat at the research table. Sayette M.A., Tiffany S.T., p. 1030-1031.
• National gambling experiences in the United States: will history repeat itself? Petry N.M., Blanco C., p. 1032-1037.
• Are the 1976-1985 birth cohorts heavier drinkers? Age-period-cohort analyses of the National Alcohol Surveys 1979-2010. Kerr W.C., Greenfield T.K., Ye Y., Bond J., Rehm J., p. 1038-1048.
• Commentary on Kerr et al. (2013): The 'French Paradox' versus binge drinking. Lanzmann-Petithory D., p. 1049-1050.
• Population drinking and drink driving in Norway and Sweden: an analysis of historical data 1957-89. Norström T., Rossow I., p. 1051-1058.
• The relationship between minimum alcohol prices, outlet densities and alcohol-attributable deaths in British Columbia, 2002-09. Zhao J., Stockwell T., Martin G., Macdonald S., Vallance K., Treno A., et al., p. 1059-1069.
• Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? de Vos A.S., van der Helm J.J., Matser A., Prins M., Kretzschmar M.E.E., p. 1070-1081.
• Commentary on de Vos et al. (2013): Can ecological trends in HIV or HCV incidence be used to assess intervention impact? Vickerman P., Hickman M., p. 1082-1083.
• A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Levin F.R., Mariani J., Brooks D.J., Pavlicova M., Nunes E.V., Agosti V., et al., p. 1084-1094.
• A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Vosburg S.K., Jones J.D., Manubay J.M., Ashworth J.B., Shapiro D.Y., Comer S.D., p. 1095-1106.
• A prospective study of neurocognitive changes 15 years after chronic inhalant abuse. Cairney S., O' Connor N., Dingwall K.M., Maruff P., Shafiq-Antonacci R., Currie J., et al., p. 1107-1114.
• 'Vaping' profiles and preferences: an online survey of electronic cigarette users. Dawkins L., Turner J., Roberts A., Soar K., p. 1115-1125.
• Commentary on Dawkins et al. (2013): The current legislation on nicotine causes millions of deaths - it has to change. Etter J.-F., p. 1126.
• Tobacco dependence diagnosis and treatment in Veterans Health Administration residential substance use disorder treatment programs. Gifford E.V., Tavakoli S., Wang R., Hagedorn H.J., Hamlett-Berry K.W., p. 1127-1135.
• Motivational interviewing to enhance nicotine patch treatment for smoking cessation among homeless smokers: a randomized controlled trial. Okuyemi K.S., Goldade K., Whembolua G.-L., Thomas J.L., Eischen S., Sewali B., et al., p. 1136-1144.
• Which elements of improvement collaboratives are most effective? A cluster-randomized trial. Gustafson D.H., Quanbeck A.R., Robinson J.M., Ford J.H., Pulvermacher A., French M.T., et al., p. 1145-1157.
• Commentary on Gustafson et al. (2013): Can we know that addiction treatment has been improved without evidence of better patient outcomes? Humphreys K., p. 1158-1159.
• Harold A. Mulford Jr, 1922-2012 [Obituary]. Roman P., p. 1160-1161.
• A critique of Minozzi et al.'s pain relief and dependence systematic review, and authors' response. McAuliffe W.E., Minozzi S., Amato L., Davoli M., p. 1162-1171.
• Misleading UK alcohol industry criticism of Canadian research on minimum pricing. Stockwell T., Zhao J., Martin G., Macdonald S., Vallance K., Treno A., et al., p. 1172-1173.
• The future of drug and alcohol libraries. Shapiro H., p. 1173-1174.
• Managing opioid dependence treatment and controlling for HIV incidence among injecting drug users in Greece: a case study of optimism in the face of adversity. Malliori M., Golna C., Souliotis K., Hatzakis A., p. 1174-1175.